Zheng Quan Shi Bao Wang·2025-09-16 00:29Core Insights - Aikobai has submitted a listing application to the Hong Kong Stock Exchange, with JPMorgan and CITIC Securities acting as joint sponsors [1] - The company was established in 2013 and focuses on discovering and developing therapies for respiratory and pediatric diseases, targeting conditions that currently lack effective treatments [1] Product Pipeline - Aikobai has a pipeline of six candidate drugs, including its core product, Ziresovir, which is in the NDA stage for RSV treatment [1] - Other candidates include AK0610, a Phase II monoclonal antibody for RSV prevention, AK3280, a Phase II drug for IPF, and AK0901, which is also in the NDA stage for ADHD treatment [1] - Additional candidates in development are AK0705 for COPD treatment and AK0406 for influenza treatment [1]